{"disease":{"id":"immune-checkpoint-inhibitor-related-colitis","name":"immune checkpoint inhibitor related colitis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06841705","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Shilpa Grover, MD, MPH","has_results":false},{"nct_id":"NCT06074874","title":"Intestinal Biomarker Analysis After ECP for ICI Colitis","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Freiburg","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}